Severe everolimus-associated pneumonitis in a renal transplant recipient

48Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Inhibitors of mTOR (mammalian target of rapamycin) are immunosuppressants with less nephrotoxic potential than calcineurin inhibitors and antiproliferative effects, which are advantageous in the case of malignancy. However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis. To our knowledge, only one case of a pneumonitis associated with everolimus in a heart transplant patient has been reported, and it was related to elevated trough blood levels. We report herein the first case of a kidney graft recipient who developed everolimus-associated pneumonitis with normal trough blood levels that was completely reversed after drug withdrawal. © The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Cite

CITATION STYLE

APA

Alexandru, S., Ortiz, A., Baldovi, S., Milicua, J. M., Ruíz-Escribano, E., Egido, J., & Plaza, J. J. (2008). Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrology Dialysis Transplantation, 23(10), 3353–3355. https://doi.org/10.1093/ndt/gfn401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free